Rimidi Company Overview
Rimidi is a healthcare technology company focusing on chronic disease management and remote patient monitoring, offering a management platform that combines patient-generated health data with clinical data to provide patient-specific insights and actions. Rimidi was named to AVIA Connect's Top 50 companies in remote patient monitoring in 2022 and 2023 and is a business partner of the National Association of Accountable Care Organizations. Rimidi has raised $17.2 million through investors like Turner Investments, Cox Enterprises, and Village Capital.
Rimidi Valuation History
Rimidi Stock Price
The stock price of Rimidi can be calculated by taking the valuation of the company divided by the number of shares outstanding. Because a private company can issue new shares at any time, we do not know the current number of shares outstanding.
For illustrative purposes, however, assuming Rimidi has issued 250 million shares, at the estimated UpMarket valuation of $31.75 million, each share of Rimidi stock would be worth $0.13.
Buy Rimidi Stock
If you would like to buy shares in Rimidi, please provide your information in the form at the top of this page and click the button titled “I want to buy this stock.”
One of our investor relations team members will contact you to discuss Rimidi stock availability. Note: inquiries are non-binding and shares may only be purchased by accredited investors that meet all eligibility criteria.
UpMarket has offered many similar companies as Pre-IPO investments, including Airbnb, SpaceX, ByteDance, Plaid, Kraken, Databricks, and others. UpMarket also often has funds available that invest in a portfolio of companies potentially including, Rimidi as well.
Rimidi Management
Name | Position |
---|---|
Lucienne Ide | CEO |
Catriona Tarto | CTO |
Janyl Jentlie | COO |